Rockwell Medical (NASDAQ:RMTI - Get Free Report) had its price objective lowered by equities researchers at HC Wainwright from $9.00 to $7.00 in a research note issued on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 203.03% from the stock's previous close.
Several other research analysts have also recently issued reports on RMTI. RODMAN&RENSHAW upgraded shares of Rockwell Medical to a "strong-buy" rating in a report on Thursday, November 14th. StockNews.com cut Rockwell Medical from a "buy" rating to a "hold" rating in a research report on Thursday. Finally, Rodman & Renshaw assumed coverage on shares of Rockwell Medical in a research note on Thursday, November 14th. They issued a "buy" rating and a $5.00 price objective on the stock.
Check Out Our Latest Research Report on RMTI
Rockwell Medical Stock Performance
NASDAQ:RMTI traded up $0.06 during midday trading on Monday, reaching $2.31. 1,332,364 shares of the company traded hands, compared to its average volume of 380,596. Rockwell Medical has a twelve month low of $1.16 and a twelve month high of $5.15. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 2.00. The company has a fifty day moving average price of $3.53 and a 200 day moving average price of $2.65. The firm has a market capitalization of $74.66 million, a price-to-earnings ratio of -47.20 and a beta of 1.50.
Hedge Funds Weigh In On Rockwell Medical
A number of institutional investors have recently bought and sold shares of RMTI. XTX Topco Ltd boosted its position in shares of Rockwell Medical by 45.7% in the third quarter. XTX Topco Ltd now owns 28,455 shares of the company's stock worth $113,000 after buying an additional 8,922 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in Rockwell Medical during the 3rd quarter worth about $40,000. Verus Capital Partners LLC purchased a new position in Rockwell Medical during the 3rd quarter valued at about $51,000. State Street Corp grew its stake in Rockwell Medical by 21.5% during the 3rd quarter. State Street Corp now owns 95,004 shares of the company's stock valued at $377,000 after acquiring an additional 16,800 shares in the last quarter. Finally, Barclays PLC acquired a new position in shares of Rockwell Medical in the 3rd quarter valued at about $90,000. Hedge funds and other institutional investors own 23.31% of the company's stock.
Rockwell Medical Company Profile
(
Get Free Report)
Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
Featured Articles
Before you consider Rockwell Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rockwell Medical wasn't on the list.
While Rockwell Medical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
